{
  "total_fields": 26,
  "field_analysis": {
    "drugName": {
      "occurrences": 8,
      "max_length": 18,
      "samples": [
        "Emgality",
        "Olumiant",
        "Mounjaro"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "setId": {
      "occurrences": 8,
      "max_length": 36,
      "samples": [
        "33a147be-233a-40e8-a55e-e40936e28db0",
        "866e9f35-9035-4581-a4b1-75a621ab55cf",
        "d2d7da5d-ad07-4228-955f-cf7e355c8cc0"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "slug": {
      "occurrences": 8,
      "max_length": 17,
      "samples": [
        "emgality-33a147b",
        "olumiant-866e9f3",
        "mounjaro-d2d7da5"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "labeler": {
      "occurrences": 8,
      "max_length": 21,
      "samples": [
        "Eli Lilly and Company",
        "Eli Lilly and Company",
        "Eli Lilly and Company"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "label.genericName": {
      "occurrences": 8,
      "max_length": 17,
      "samples": [
        "galcanezumab-gnlm",
        "baricitinib",
        "tirzepatide"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "label.labelerName": {
      "occurrences": 8,
      "max_length": 21,
      "samples": [
        "Eli Lilly and Company",
        "Eli Lilly and Company",
        "Eli Lilly and Company"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "label.productType": {
      "occurrences": 8,
      "max_length": 29,
      "samples": [
        "HUMAN PRESCRIPTION DRUG LABEL",
        "HUMAN PRESCRIPTION DRUG LABEL",
        "HUMAN PRESCRIPTION DRUG LABEL"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "label.effectiveTime": {
      "occurrences": 8,
      "max_length": 8,
      "samples": [
        "20210311",
        "20241113",
        "20250114"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "label.title": {
      "occurrences": 8,
      "max_length": 9,
      "samples": [
        "EMGALITY",
        "Olumiant",
        "MOUNJARO"
      ],
      "is_html": false,
      "html_tags": [],
      "has_tables": false,
      "has_lists": false,
      "section_codes": []
    },
    "label.indicationsAndUsage": {
      "occurrences": 8,
      "max_length": 1819,
      "samples": [
        "[HTML] 1 INDICATIONS AND USAGE1.1 MigraineEMGALITY is indicated for the preventive treatment of migraine in adults.1.2 Episodic Cluster HeadacheEMGALITY is indicated for the treatment of episodic cluster hea..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "section",
        "h2",
        "span",
        "p",
        "li",
        "ul",
        "h1",
        "div"
      ],
      "has_tables": false,
      "has_lists": true,
      "section_codes": [
        "42229-5",
        "34067-9"
      ]
    },
    "label.dosageAndAdministration": {
      "occurrences": 8,
      "max_length": 28011,
      "samples": [
        "[HTML] 2 DOSAGE AND ADMINISTRATION2.1 Recommended Dosing for MigraineThe recommended dosage of EMGALITY is 240\u00a0mg (two consecutive subcutaneous injections of 120\u00a0mg each) once as a loading dose, followed by ..."
      ],
      "is_html": true,
      "html_tags": [
        "caption",
        "br",
        "li",
        "dl",
        "ul",
        "dt",
        "h1",
        "td",
        "ol",
        "tfoot",
        "col",
        "dd",
        "h2",
        "a",
        "section",
        "tr",
        "tbody",
        "p",
        "table",
        "div",
        "span"
      ],
      "has_tables": true,
      "has_lists": true,
      "section_codes": [
        "34068-7",
        "42229-5",
        "43678-2"
      ]
    },
    "label.dosageFormsAndStrengths": {
      "occurrences": 8,
      "max_length": 732,
      "samples": [
        "[HTML] 3 DOSAGE FORMS AND STRENGTHSEMGALITY is a sterile clear to opalescent, colorless to slightly yellow to slightly brown solution available as follows:Injection: 120\u00a0mg/mL in a single-dose prefilled penI..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "section",
        "h2",
        "p",
        "li",
        "ul",
        "h1"
      ],
      "has_tables": false,
      "has_lists": true,
      "section_codes": [
        "43678-2"
      ]
    },
    "label.warningsAndPrecautions": {
      "occurrences": 8,
      "max_length": 16504,
      "samples": [
        "[HTML] 5 WARNINGS AND PRECAUTIONS5.1 Hypersensitivity ReactionsHypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with EMGALITY in clinical studies and the postmarketing settin..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "section",
        "h2",
        "span",
        "p",
        "li",
        "ul",
        "h1",
        "div"
      ],
      "has_tables": false,
      "has_lists": true,
      "section_codes": [
        "43685-7",
        "42229-5"
      ]
    },
    "label.adverseReactions": {
      "occurrences": 8,
      "max_length": 79905,
      "samples": [
        "[HTML] 6 ADVERSE REACTIONSThe following clinically significant adverse reactions are described elsewhere in the labeling:Hypersensitivity Reactions[see Contraindications (4) and Warnings and Precautions (5.1..."
      ],
      "is_html": true,
      "html_tags": [
        "caption",
        "br",
        "li",
        "ul",
        "td",
        "h1",
        "tfoot",
        "col",
        "h2",
        "th",
        "a",
        "section",
        "tr",
        "tbody",
        "p",
        "table",
        "div",
        "thead",
        "span"
      ],
      "has_tables": true,
      "has_lists": true,
      "section_codes": [
        "88830-5",
        "34084-4",
        "90374-0",
        "90375-7",
        "42229-5"
      ]
    },
    "label.clinicalPharmacology": {
      "occurrences": 8,
      "max_length": 15123,
      "samples": [
        "[HTML] 12 CLINICAL PHARMACOLOGY12.1 Mechanism of ActionGalcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor...."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "caption",
        "section",
        "h2",
        "span",
        "br",
        "tfoot",
        "tr",
        "p",
        "tbody",
        "table",
        "td",
        "h1",
        "div",
        "img",
        "col"
      ],
      "has_tables": true,
      "has_lists": false,
      "section_codes": [
        "43681-6",
        "88830-5",
        "43679-0",
        "34090-1",
        "43682-4",
        "42229-5"
      ]
    },
    "label.clinicalStudies": {
      "occurrences": 8,
      "max_length": 97461,
      "samples": [
        "[HTML] 14 CLINICAL STUDIES14.1 MigraineThe efficacy of EMGALITY was evaluated as a preventive treatment of episodic or chronic migraine in three multicenter, randomized, double-blind, placebo-controlled stud..."
      ],
      "is_html": true,
      "html_tags": [
        "caption",
        "br",
        "li",
        "dl",
        "ul",
        "td",
        "h1",
        "dt",
        "ol",
        "tfoot",
        "col",
        "dd",
        "h2",
        "a",
        "section",
        "tr",
        "tbody",
        "p",
        "table",
        "div",
        "img",
        "span"
      ],
      "has_tables": true,
      "has_lists": true,
      "section_codes": [
        "42229-5",
        "34092-7"
      ]
    },
    "label.howSupplied": {
      "occurrences": 8,
      "max_length": 2905,
      "samples": [
        "[HTML] 16.1 How SuppliedEMGALITY (galcanezumab-gnlm) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution for subcutaneous administration.EM..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "h2",
        "section",
        "tr",
        "span",
        "tbody",
        "br",
        "p",
        "li",
        "table",
        "ul",
        "td",
        "h1",
        "col"
      ],
      "has_tables": true,
      "has_lists": true,
      "section_codes": [
        "34069-5"
      ]
    },
    "label.useInSpecificPopulations": {
      "occurrences": 8,
      "max_length": 12370,
      "samples": [
        "[HTML] 8 USE IN SPECIFIC POPULATIONS8.1 PregnancyPregnancy Exposure RegistryThere is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to EMGALITY during pregnancy. Healthcare p..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "section",
        "h2",
        "span",
        "p",
        "h1",
        "div"
      ],
      "has_tables": false,
      "has_lists": false,
      "section_codes": [
        "77291-3",
        "88829-7",
        "42228-7",
        "77290-5",
        "34082-8",
        "43684-0",
        "88828-9",
        "34081-0",
        "42229-5"
      ]
    },
    "label.description": {
      "occurrences": 8,
      "max_length": 2322,
      "samples": [
        "[HTML] 11 DESCRIPTIONGalcanezumab-gnlm is a humanized IgG4 monoclonal antibody specific for calcitonin-gene related peptide (CGRP) ligand. Galcanezumab-gnlm is produced in Chinese Hamster Ovary (CHO) cells b..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "span",
        "section",
        "p",
        "h1",
        "div",
        "img"
      ],
      "has_tables": false,
      "has_lists": false,
      "section_codes": [
        "34089-3"
      ]
    },
    "label.nonclinicalToxicology": {
      "occurrences": 8,
      "max_length": 3621,
      "samples": [
        "[HTML] 13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityCarcinogenesisThe carcinogenic potential of galcanezumab-gnlm has not been assessed.MutagenesisGenetic toxicology stud..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "section",
        "h2",
        "span",
        "p",
        "h1",
        "div"
      ],
      "has_tables": false,
      "has_lists": false,
      "section_codes": [
        "34091-9",
        "42229-5",
        "43680-8",
        "34083-6"
      ]
    },
    "label.instructionsForUse": {
      "occurrences": 5,
      "max_length": 22322,
      "samples": [
        "[HTML] INSTRUCTIONS FOR USEEMGALITY\u00ae(em-GAL-it-\u0113)(galcanezumab-gnlm)injection, for subcutaneous usePrefilled SyringeThis Instructions for Use is for patients with episodic cluster headache.If you are using E..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "dd",
        "section",
        "span",
        "tr",
        "br",
        "tbody",
        "p",
        "li",
        "table",
        "dl",
        "ul",
        "td",
        "dt",
        "h1",
        "div",
        "img",
        "col"
      ],
      "has_tables": true,
      "has_lists": true,
      "section_codes": [
        "59845-8"
      ]
    },
    "label.mechanismOfAction": {
      "occurrences": 8,
      "max_length": 1269,
      "samples": [
        "[HTML] 12.1 Mechanism of ActionGalcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor...."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "h2",
        "p",
        "section"
      ],
      "has_tables": false,
      "has_lists": false,
      "section_codes": [
        "43679-0"
      ]
    },
    "label.contraindications": {
      "occurrences": 8,
      "max_length": 756,
      "samples": [
        "[HTML] 4 CONTRAINDICATIONSEMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients[see Warnings and Precautions (5.1)]...."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "span",
        "section",
        "p",
        "li",
        "ul",
        "h1"
      ],
      "has_tables": false,
      "has_lists": true,
      "section_codes": [
        "34070-3"
      ]
    },
    "label.highlights.dosageAndAdministration": {
      "occurrences": 8,
      "max_length": 2253,
      "samples": [
        "[HTML] For subcutaneous use only. (2.1,2.2,2.3)Migraine recommended dosage: 240\u00a0mg loading dose (administered as two consecutive injections of 120\u00a0mg each), followed by monthly doses of 120\u00a0mg. (2.1)Episodic..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "span",
        "p",
        "li",
        "ul",
        "div"
      ],
      "has_tables": false,
      "has_lists": true,
      "section_codes": []
    },
    "label.boxedWarning": {
      "occurrences": 3,
      "max_length": 1841,
      "samples": [
        "[HTML] WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSISSee full prescribing information for complete boxed warning.Increased risk of serious bact..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "span",
        "h2",
        "li",
        "p",
        "ul",
        "div",
        "h1"
      ],
      "has_tables": false,
      "has_lists": true,
      "section_codes": []
    },
    "label.drugInteractions": {
      "occurrences": 5,
      "max_length": 2951,
      "samples": [
        "[HTML] 7 DRUG INTERACTIONS7.1 Strong OAT3 InhibitorsBaricitinib exposure is increased when OLUMIANT is co-administered with strong OAT3 inhibitors (such as probenecid), hence the dosage of baricitinib should..."
      ],
      "is_html": true,
      "html_tags": [
        "a",
        "section",
        "h2",
        "span",
        "p",
        "h1",
        "div"
      ],
      "has_tables": false,
      "has_lists": false,
      "section_codes": [
        "42229-5",
        "34073-7"
      ]
    }
  },
  "html_fields": [
    "label.indicationsAndUsage",
    "label.dosageAndAdministration",
    "label.dosageFormsAndStrengths",
    "label.warningsAndPrecautions",
    "label.adverseReactions",
    "label.clinicalPharmacology",
    "label.clinicalStudies",
    "label.howSupplied",
    "label.useInSpecificPopulations",
    "label.description",
    "label.nonclinicalToxicology",
    "label.instructionsForUse",
    "label.mechanismOfAction",
    "label.contraindications",
    "label.highlights.dosageAndAdministration",
    "label.boxedWarning",
    "label.drugInteractions"
  ],
  "key_sections": [
    "label.indicationsAndUsage",
    "label.dosageAndAdministration",
    "label.dosageFormsAndStrengths",
    "label.warningsAndPrecautions",
    "label.adverseReactions",
    "label.clinicalPharmacology",
    "label.clinicalStudies",
    "label.nonclinicalToxicology",
    "label.contraindications",
    "label.highlights.dosageAndAdministration",
    "label.boxedWarning"
  ],
  "data_structure": {
    "drugName": {
      "type": "text",
      "occurrences": 8
    },
    "setId": {
      "type": "text",
      "occurrences": 8
    },
    "slug": {
      "type": "text",
      "occurrences": 8
    },
    "labeler": {
      "type": "text",
      "occurrences": 8
    },
    "label": {
      "genericName": {
        "type": "text",
        "occurrences": 8
      },
      "labelerName": {
        "type": "text",
        "occurrences": 8
      },
      "productType": {
        "type": "text",
        "occurrences": 8
      },
      "effectiveTime": {
        "type": "text",
        "occurrences": 8
      },
      "title": {
        "type": "text",
        "occurrences": 8
      },
      "indicationsAndUsage": {
        "type": "html",
        "occurrences": 8
      },
      "dosageAndAdministration": {
        "type": "html",
        "occurrences": 8
      },
      "dosageFormsAndStrengths": {
        "type": "html",
        "occurrences": 8
      },
      "warningsAndPrecautions": {
        "type": "html",
        "occurrences": 8
      },
      "adverseReactions": {
        "type": "html",
        "occurrences": 8
      },
      "clinicalPharmacology": {
        "type": "html",
        "occurrences": 8
      },
      "clinicalStudies": {
        "type": "html",
        "occurrences": 8
      },
      "howSupplied": {
        "type": "html",
        "occurrences": 8
      },
      "useInSpecificPopulations": {
        "type": "html",
        "occurrences": 8
      },
      "description": {
        "type": "html",
        "occurrences": 8
      },
      "nonclinicalToxicology": {
        "type": "html",
        "occurrences": 8
      },
      "instructionsForUse": {
        "type": "html",
        "occurrences": 5
      },
      "mechanismOfAction": {
        "type": "html",
        "occurrences": 8
      },
      "contraindications": {
        "type": "html",
        "occurrences": 8
      },
      "highlights": {
        "dosageAndAdministration": {
          "type": "html",
          "occurrences": 8
        }
      },
      "boxedWarning": {
        "type": "html",
        "occurrences": 3
      },
      "drugInteractions": {
        "type": "html",
        "occurrences": 5
      }
    }
  }
}